{"DataElement":{"publicId":"2492995","version":"1","preferredName":"Prior Hormonal Therapy Therapy Text Name","preferredDefinition":"Text term(s) to represent the name(s) of hormonal agent(s) administered to an individual on a research protocol.","longName":"PRIOR_HORM_TX_TXT_NM","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2188728","version":"1","preferredName":"Prior Hormonal Therapy Administered","preferredDefinition":"information related to prior hormonal therapy administered.","longName":"PRIOR_HORMONALTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206567","version":"1","preferredName":"Prior Hormone Therapy","preferredDefinition":"Earlier in time or order.:Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C25629:C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FA31-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E54DEC97-5F79-61C9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2492992","version":"1","preferredName":"Hormonal Therapy Text Name","preferredDefinition":"Text terms to represent the name(s) of hormonal agents given in research protocols.","longName":"HORM_TX_TXT_NM","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"28","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Exemetastane (Aromasin)","valueDescription":"Exemetastane","ValueMeaning":{"publicId":"2580126","version":"1","preferredName":"Exemetastane","longName":"2580126","preferredDefinition":"Exemetastane","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-060B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2006-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"174E9B2C-3980-3836-E044-0003BA3F9857","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2006-06-28","deletedIndicator":"No"},{"value":"Anastrozole (Arimidex)","valueDescription":"ANASTROZOLE","ValueMeaning":{"publicId":"2561407","version":"1","preferredName":"ANASTROZOLE","longName":"2561407","preferredDefinition":"ANASTROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"174EBC53-6893-3BA1-E044-0003BA3F9857","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2006-06-28","deletedIndicator":"No"},{"value":"Letrozole (Femara)","valueDescription":"LETROZOLE","ValueMeaning":{"publicId":"2561408","version":"1","preferredName":"LETROZOLE","longName":"2561408","preferredDefinition":"LETROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"174EBC53-68A8-3BA1-E044-0003BA3F9857","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2006-06-28","deletedIndicator":"No"},{"value":"Tamoxifen (Nolvadex)","valueDescription":"TAMOXIFEN","ValueMeaning":{"publicId":"2561706","version":"1","preferredName":"TAMOXIFEN","longName":"2561706","preferredDefinition":"TAMOXIFEN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"174EBC53-68BD-3BA1-E044-0003BA3F9857","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2006-06-28","deletedIndicator":"No"},{"value":"Megestrol Acetate (Megace)","valueDescription":"Megestrol Acetate","ValueMeaning":{"publicId":"2580127","version":"1","preferredName":"Megestrol Acetate","longName":"2580127","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-060C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"ONEDATA","dateModified":"2006-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"174EBC53-68D5-3BA1-E044-0003BA3F9857","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2006-06-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261898","version":"1","preferredName":"Text Name","preferredDefinition":"Text; the words of something written.:The words or language units by which a thing is known.","longName":"C25704:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBDEE8CB-7C8A-5E8A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"ONEDATA","dateModified":"2005-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"174E9B64-7AAC-376A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812815","version":"1","longName":"Albert Einstein New CDEs","context":"NCIP"},{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812573","version":"1","longName":"Albert Einstein Medical Center","context":"NCIP"},{"publicId":"2812812","version":"1","longName":"AE_104_085","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior Hormonal Therapy","type":"Preferred Question Text","description":"Prior Hormonal Therapy","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"174EC582-7C6D-3D5F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"REEVESD","dateModified":"2007-06-21","changeDescription":"Curated to support Albert Einstein adoption of C3D.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}